Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by SHIM, S. S. Search for Related Content PubMed Citation Articles by SHIM, S. S. Neurotransmitters

Action of Atypical Antipsychotics

To the Editor: Drs. Kapur and Seeman proposed an interesting hypothesis that fast dissociation from D₂ receptors explains the action of atypical antipsychotic agents. I propose that the lower affinity—the lower ratio of k_on (association rate constant) to k_off (dissociation rate constant)—of D₂ receptors explains the action of atypical antipsychotics. I will discuss this hypothesis on molecular and systemic levels, as the authors did.

The authors’ hypothesis derives from two intriguing experimental findings at the molecular level. First, differences in the affinity of antipsychotic agents for D₂ receptors are driven by differences between their k_off, not between their k_on. Second, atypical antipsychotic agents have much higher k_off (fast k_off) at D₂ receptors than do typical antipsychotic agents. On the basis of these findings, the authors hypothesized that the action of atypical antipsychotic agents may derive from faster dissociation from D₂ receptors and explained that "when the concentration of endogenous dopamine rises in response to physiological stimuli, drugs like clozapine (which have a nearly 100 times faster k_off [than haloperidol]) decrease their occupancy much faster and provide much more access to surges of dopamine" (p. 364). According to receptor binding kinetics, antipsychotic agents and endogenous dopamine compete with each other to occupy D₂ receptors because of their affinities for D₂ receptors. Since the affinity of an antipsychotic agent is determined by the ratio of k_on to k_off, the degree of unoccupied receptor accessible to endogenous dopamine is determined not only by how quickly the drugs dissociate from D₂ receptors but also by how slowly the drugs associate to D₂ receptors. Thus, antipsychotic agents with slower k_on can provide more access to surges of dopamine, as antipsychotic agents with faster k_off do. Although the atypical antipsychotic agents that the authors have tested so far showed faster k_off, it is always possible that newer atypical antipsychotic agents have low affinity and slower k_on, rather than faster k_off. Thus, faster k_off is not the exclusive criterion for the atypical action of antipsychotic agents, but the lower affinity and faster k_off and/or slower k_on are the criteria for the atypical action of antipsychotic agents.

At the systemic level, the authors proposed that the much more transient occupancy of the D₂ receptors by atypical antipsychotic agents is associated with transient prolactin elevation and fewer extrapyramidal side effects (1). The authors claimed that this transient effect is accounted for by faster k_off. However, the transient occupancy of D₂ receptors by single doses of atypical agents may not exactly reflect the pattern of D₂ receptor occupancy when patients reach a plateau after multiple doses of the drugs, by which time D₂ receptor occupancy would be greatly prolonged. Another potential problem with the theory for the transient occupancy of D₂ receptors by atypical antipsychotic agents is its relationship with the onset of clinical response. A large body of evidence indicates that dopamine cell activity is dramatically reduced and that, subsequently, release of endogenous dopamine is greatly reduced within 2–3 weeks of drug administration (2). Clinical response is usually shown within 2–3 weeks of the administration of antipsychotic agents. At this time, atypical antipsychotic agents may occupy D₂ receptors much more because the synaptic concentration of dopamine is greatly reduced. Thus, D₂ receptor occupancy by the atypicals at or after this point in time may be more relevant to the drugs’ antipsychotic action.

References

1. Jones C, Kapur S, Remington G, Zipursky RB: Transient dopamine D2 occupancy in low EPS-incidence drugs: PET evidence (abstract). Biol Psychiatry 2000; 47(suppl 8):112
2. Chiodo LA, Bunney BS: Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopamine neurons. J Neurosci 1983; 3:1607-1619[Abstract]

This article has been cited by other articles:

				I. Tofler Olanzapine and Neuroleptic Malignant Syndrome Psychosomatics, December 1, 2002; 43(6): 505 - 506. [Full Text] [PDF]

Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by SHIM, S. S. Search for Related Content PubMed Citation Articles by SHIM, S. S. Neurotransmitters

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us